Immutep Limited CEO & Executive Director, Marc Voigt, provides an update on the company's clinical trials, including its Phase IIb AIPAC study into metastatic breast cancer.
Jessica Amir: So first up, you've got a lot of data coming out in the coming months. Just tell us what we can expect.
Marc Voigt: Yeah, we really have a lot of data coming from almost all of our clinical trials, especially for Eftilagimod alpha, our only product candidate, the immune modulator. So there we have AIPAC, our largest clinical trial. We expect data in first quarter next calendar year. We have TACTI-mel final data towards end of this year. In sight, there should also be data later this year as well as TACTI-002, a trial which we conduct together with Merck (NYSE:MRK), and there we expect also data already mid of this year and then later this year as well.
https://www.finnewsnetwork.com.au/archives/finance_news_network233327.html
- Forums
- ASX - By Stock
- IMM
- Immutep (ASX:IMM) clinical trial update @July 02, 2019 02:45 PM
Immutep (ASX:IMM) clinical trial update @July 02, 2019 02:45 PM
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
29.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $428.5M |
Open | High | Low | Value | Volume |
30.0¢ | 30.5¢ | 28.5¢ | $715.2K | 2.430M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
10 | 305228 | 29.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
29.5¢ | 36744 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
10 | 305228 | 0.290 |
24 | 544409 | 0.285 |
11 | 216592 | 0.280 |
4 | 113663 | 0.275 |
15 | 305814 | 0.270 |
Price($) | Vol. | No. |
---|---|---|
0.295 | 36744 | 2 |
0.300 | 220559 | 13 |
0.305 | 178280 | 11 |
0.310 | 273999 | 6 |
0.315 | 110917 | 5 |
Last trade - 16.10pm 08/07/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |